Prions, infectious agents associated with prion diseases such as Creutzfeldt-Jakob disease in humans, bovine spongiform encephalopathy (BSE) in cattle, and scrapie in sheep and goats, are primarily comprised of PrPSc, a protease-resistant misfolded isoform of the cellular prion protein PrPC. Protein misfolding cyclic amplification (PMCA) is a highly sensitive technique used to detect minute amounts of scrapie PrPSc. However, the current PMCA technique has been unsuccessful in achieving good amplification in cattle. The detailed distribution of PrPSc in BSE-affected cattle therefore remains unknown.
We report here that PrPSc derived from BSE-affected cattle can be amplified ultra-efficiently by PMCA in the presence of sulfated dextran compounds. This method is capable of amplifying very small amounts of PrPSc from the saliva, palatine tonsils, lymph nodes, ileocecal region, and muscular tissues of BSE-affected cattle. Individual differences in the distribution of PrPSc in spleen and cerebrospinal fluid samples were observed in terminal-stage animals. However, the presence of PrPSc in blood was not substantiated in the BSE-affected cattle examined.
The distribution of PrPSc is not restricted to the nervous system and can spread to peripheral tissues in the terminal disease stage. The finding that PrPSc could be amplified in the saliva of an asymptomatic animal suggests a potential usefulness of this technique for BSE diagnosis. This highly sensitive method also has other practical applications, including safety evaluation or safety assurance of products and byproducts manufactured from bovine source materials.
Citation: Murayama Y, Yoshioka M, Masujin K, Okada H, Iwamaru Y, Imamura M, et al. (2010) Sulfated Dextrans Enhance In Vitro Amplification of Bovine Spongiform Encephalopathy PrPSc and Enable Ultrasensitive Detection of Bovine PrPSc. PLoS ONE 5(10): e13152. https://doi.org/10.1371/journal.pone.0013152
Editor: Karin E. Peterson, Rocky Mountain Laboratories, NIAID, NIH, United States of America
Received: July 5, 2010; Accepted: September 12, 2010; Published: October 4, 2010
Copyright: © 2010 Murayama et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by a grant-in-aid from the BSE Control Project of the Ministry of Agriculture, Forestry and Fisheries of Japan. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Prions, the infectious agents associated with transmissible spongiform encephalopathies such as scrapie in sheep, chronic wasting disease (CWD) in deer and elk, bovine spongiform encephalopathy (BSE), and Creutzfeldt-Jakob disease (CJD) in humans, are primarily comprised of PrPSc, a protease-resistant misfolded isoform of the cellular prion protein PrPC . Prion diseases are fatal neurodegenerative disorders, and are characterized by the accumulation of PrPSc in the nervous tissues of infected subjects .
BSE is an emerging disease that first appeared in the United Kingdom in 1986 . The cause of the BSE outbreak in the UK is believed to have been the result of feeding cattle meat and bone meal (MBM) contaminated with PrPSc acquired from rendering carcasses of BSE- or scrapie-infected ruminants , . Since variant CJD (vCJD) is suspected to be attributable to infectious agents associated with BSE –, prophylactic hygiene dictates that infected cattle be identified and eradicated.
Immunological methods such as enzyme-linked immunosorbent assays and western blotting (WB) have been widely used for the detection of PrPSc. It is now possible to perform in vitro amplification of hamster scrapie PrPSc using the protein misfolding cyclic amplification (PMCA) technique . Extremely small amounts of PrPSc can be detected by combining PMCA with WB , . PMCA has been used to amplify PrPSc from mice , deer , sheep , and humans . PMCA has also been applied to the detection of bovine PrPSc in cattle , and serial PMCA has been shown to improve detection sensitivity . Although hyperefficient amplification of a mouse-adapted BSE strain has been demonstrated , there are no reports that cite ultrasensitive and direct detection of bovine PrPSc in cattle using the current PMCA method.
Since the concentration of PrPSc in tissues or body fluids of BSE-infected animals is expected to be extremely low, the development of a sensitive method for detecting PrPSc in infected cattle is important. In the present study, we developed an extremely efficient method that is suitable for bovine PrPSc amplification. The method, which involves amplifying BSE PrPSc in the presence of sulfated dextran compounds, enables sensitive detection of PrPSc at levels equivalent to those obtained for detection of hamster PrPSc . This method is capable of amplifying very small amounts of PrPSc from the saliva, palatine tonsils, lymph nodes, ileocecal region, and muscular tissues of BSE-affected cattle. The technology will result in a marked improvement in BSE safety.
Sulfated dextran compounds enhanced BSE PrPSc amplification
In general, the efficiency of BSE PrPSc amplification using PMCA was low compared to amplification of hamster and mouse scrapie PrPSc (Figure 1A). We attempted to improve BSE PrPSc amplification efficiency using high temperature conditions (39°C and higher). Various reagents were screened for their ability to prevent thermal denaturation of the brain homogenate, and we found that sulfated dextran compounds were suitable for this purpose. Unexpectedly, the BSE PrPSc amplification efficiency was greatly increased when amplification was performed in the presence of sulfated dextran compounds at 37°C.
A. The effect of sodium dextran sulfate with a high molecular weight (MW) ranging from 900 to 2000 kDa (sodium dextran sulfate, DSS-H) on BSE-PrPSc amplification. The PrPSc seed (10% brain homogenate) was diluted to 10−2 to 10−3 in PrPC substrate, and the diluted samples were amplified in the presence of DSS-H at 0–1%. The samples before (left panel) and after (right panel) amplification were analyzed by WB after digestion with PK. “N” designates controls in which the PrPC substrate alone was treated in the same manner. B. The effect of dextran compounds on BSE-PrPSc amplification. The PrPSc seed was diluted to 10−4, and amplification was performed in the presence or absence (“No additive”) of dextran compounds at 0.5%. “No seed” designates the control in which the PrPC substrate alone was amplified without dextran compounds. DSS-L: sodium dextran sulfate with a low MW, ranging from 5 to 6 kDa; DSP: potassium dextran sulfate (1.5 to 1.9 kDa); DEAE-dextran hydrochloride (50 kDa); dextran I (15–20 kDa), II (35–50 kDa), III (50–70 kDa), IV (200 kDa), and V (190–230 kDa). C. The effect of glycosaminoglycans (sodium chondroitin sulfate C: CSS; sodium heparan sulfate: HSS; heparan sulfate proteoglycan: HSPG) and a sulfated polysaccharide (λ-carrageenan: λ-Cag) on BSE-PrPSc amplification. The PrPSc seed was diluted to 10−4, and amplification was performed in the presence of each reagent at the final concentration indicated in the figure.
The signal intensities of amplified PrPSc upon WB were significantly higher in samples containing sodium dextran sulfate with a high molecular weight of 900–2000 kDa (DSS-H) at a final concentration of 0.25–1% (Figure 1A, right panel). This enhancement was dependent upon the polarity and molecular size of the dextran compound. Smaller anionic sodium dextran sulfate (DSS-L) and potassium dextran sulfate (DSP) were more effective than the high molecular weight compounds, but positively charged DEAE-dextran and dextrans covering a range of molecular weights had little or no effect on amplification (Figure 1B). Glycosaminoglycans that are distributed throughout animal tissues and a sulfated polysaccharide were not effective at the concentrations examined (Figure 1C).
In contrast, in vitro amplification of sheep scrapie PrPSc was completely inhibited by the addition of DSP to the reaction mixture (Figure 2A). A similarly inconsistent experimental result was obtained with pentosan polysulfate (PPS), which may be effective in treating CJD , . This reagent acted as an inhibitor of sheep scrapie PrPSc amplification (Figure 2A), but induced a low-level, dose-dependent amplification of BSE PrPSc (Figure 2B).
A. The PrPSc seed (10% brain homogenate from scrapie-infected sheep) was diluted to 10−3, and amplification was performed in the presence or absence (“No additive”) of sulfated compounds (potassium dextran sulfate: DSP and pentosan polysulfate: PPS). “No seed” designates the control in which PrPC substrate (10% homogenate of normal mouse brain) was amplified without sulfated compounds. B. Negative symbols indicate the results obtained for the control samples without BSE PrPSc seed, while positive symbols indicate the results obtained for the samples containing BSE PrPSc seed diluted to 10−4. Amplification was performed in the presence of PPS at the concentrations indicated.
Detection limit of BSE PrPSc using DSP-PMCA techniques
The optimal concentration of DSP was estimated to be in the range of 0.05–0.75% (Figure 3); therefore, we used 0.5% DSP for subsequent experiments. We determined the detection limit of the DSP-PMCA technique and confirmed that PrPSc present in a 10−6 dilution of infected brain homogenate could be detected after one round of amplification, and both 10−8 and 10−9 dilutions tested positive for PrPSc after two rounds of amplification (Figure 4A). A PrPSc signal was detected in one of the 10−10 dilution samples, but no signal was detected in the more extreme dilution range, even after four rounds of amplification. Thus, the PrPSc detection sensitivity was improved 108 times compared to no amplification. The 50% lethal dose (LD50) per gram of brain homogenate used as seed was determined in a previous study  by a bioassay using Tg(BoPrP)4092HOZ/Prnp0/0 (TgBoPrP) transgenic mice . The infectious titer was 106.7 LD50/g, and infectivity was confirmed in mice intracerebrally inoculated with up to a 10−4 dilution of the 10% brain homogenate. Therefore, our improved method was 105 times more sensitive than the bioassay. The generation of spontaneous PrPSc, as has been reported for amplification in the presence of polyanions , , was not observed with four rounds of amplification (Figure 4B).
The PrPSc seed was diluted to 10−4, and amplification was performed in the presence of the potassium dextran sulfate (DSP). “N” designates the control in which only PrPC substrate was amplified.
A. The PrPSc seed was diluted to 10−4 to 10−11 with PrPC substrate, and samples were serially amplified in the presence of 0.5% potassium dextran sulfate (DSP). The duplicate amplified samples were analyzed after each round of amplification (R1–R4) by WB after PK digestion. B. No spontaneous generation of PrPSc was observed. Samples labeled “1” to “8” contained only PrPC substrate and were amplified in the presence of 0.5% DSP.
Infectivity of the PMCA product
The PMCA product obtained after six rounds of amplification was diluted 10-fold and inoculated intracerebrally into TgBoPrP transgenic mice that overexpress bovine PrPC. Mice inoculated with the PMCA sample died after a mean of 243 days (Table 1). Control mice administered DSP (0.05%) or PrPSc (3.2×10−12 dilution) at concentrations corresponding to the BSE seed dilution in the PMCA sample survived more than 500 days. The results of immunohistochemical analysis of the habenular nuclei and the midbrains from control and treated mice are shown in Figure 5. Vacuolation and PrPSc accumulation, which was occasionally observed as plaque-like PrPSc aggregates, were found in mice inoculated with the PMCA sample or the BSE-affected cattle brain homogenate, indicating that the amplified PrPSc was infectious and caused lesions typical of prion diseases.
Results from mice inoculated with a 10% brain homogenate from BSE-infected cattle are shown for comparison. No vacuolation or PrPSc accumulation was observed in the control mice inoculated with 0.05% DSP.
PrPSc distribution in the tissues of BSE-affected cattle
Using our improved method, the distribution of PrPSc was examined in cattle that were orally administered a brain homogenate prepared from BSE-infected cattle. In the terminal disease stage in BSE-affected cow 5550, PrPSc was detected by conventional WB in several peripheral nervous tissues and the adrenal glands (Table 2). Moreover, PrPSc was detected by serial DSP-PMCA in the palatine tonsils, lymph nodes, ileocecal region, and muscular tissues (Figure 6A), whereas no PrPSc signal was detected in the corresponding tissue samples from uninfected control cow 2914 (Table 2 and Figure 6B).
A. Tissue distribution of PrPSc in the terminal disease stage in cow 5550. Quadruplicate samples of each tissue and bodily fluid were serially amplified, and the samples were analyzed after each round of amplification (R1–R4) by WB after digestion with PK. Horizontal lines indicate the positions of molecular weight markers corresponding to 37 kDa, 25 kDa, 20 kDa, and 15 kDa. Ns: No seed control. B. Negative control reaction for serial PMCA in each tissue. Quadruplicate samples of each tissue and bodily fluid from uninfected cow 2914 were serially amplified, and the samples were analyzed by WB following digestion with PK after each round of amplification. C: Cervical region, T: Thoracic region, L: Lumbar region, nt: Not tested.
We could not detect PrPSc in the spleen, blood, or cerebrospinal fluid (CSF) from BSE-affected cow 5550 in the end stage of disease, even after four rounds of amplification. Although an additional five tissue pieces were cut from both the central portion of the spleen and the splenic hilum for amplification, splenic PrPSc was not detected in any of these 10 tissue samples (Figure 7A). The distribution of PrPSc in the spleen was examined further in two more terminal disease-stage BSE-affected cattle, numbers 5499 and 5468. As was the case with cow 5550, splenic PrPSc was not detected in any of the 10 tissue samples from cow 5499 (Figure 7B). However, a PrPSc signal was detected in 3 of 10 tissue pieces from the spleen of cow 5468 (Figure 7C).
A total of 10 tissue pieces (0.2 g each) were cut from the central portion of the spleen (a–e) and splenic hilum (f–j) for amplification. Duplicate samples of spleen tissue from BSE-affected cows 5550 (A), 5499 (B), and 5468 (C) were examined. Blood and CSF samples from cows 5499 (B) and 5468 (C) were also examined. Horizontal lines indicate the positions of molecular weight markers corresponding to 37 kDa, 25 kDa, 20 kDa, and 15 kDa. WBC: White blood cells, CSF: Cerebrospinal fluid, Ns: No seed control.
PrPSc distribution in the bodily fluids of BSE-affected cattle
Before amplification, PrPSc accumulation was confirmed using conventional WB analysis in the peripheral nervous tissues of cows 5499 and 5468 and in the adrenal gland of cow 5468 (Table 2). Individual differences in the distribution of PrPSc in CSF samples were observed in terminal-stage animals. PrPSc signals were detected in duplicate samples from cow 5468 after three rounds of amplification (Figure 7C) but were not detected in samples from cow 5499 (Figure 7B), as confirmed in samples from cow 5550 (Figure 6A).
We also examined the distribution of PrPSc in the salivary glands and saliva obtained from BSE-affected cattle. PrPSc was detected in the submandibular and parotid glands of cows 5468 and 5499 after two rounds of amplification (Figure 8A). In cow 5550, PrPSc was detected in the submandibular and sublingual glands (Figure 8B). Moreover, a PrPSc signal was detected in two of the quadruplicate saliva samples from cow 5550 after four rounds of amplification. The presence or absence of salivary PrPSc was investigated in intracerebrally infected cow 9007. PrPSc accumulation in the brain stem was found by conventional WB analysis 17 months after inoculation (Table 2), but the animal remained asymptomatic until sacrifice. PrPSc was detected in the sublingual and parotid glands after two rounds of amplification. In cow 9007, one of the duplicate saliva samples was found to be positive for PrPSc after four rounds of amplification (Figure 8C).
Salivary PrPSc was evaluated in samples from an uninfected control cow (5660) and samples obtained from BSE-inoculated cows (5468, 5499, and 5550) in the terminal disease stage. Salivary PrPSc was also evaluated in an asymptomatic cow (9007) that had been intracerebrally inoculated with BSE. Horizontal lines indicate the positions of molecular weight markers corresponding to 37 kDa, 25 kDa, 20 kDa, and 15 kDa. Ns: No seed control.
The present study is the first report describing ultrasensitive detection of BSE PrPSc in cattle. The determination that sulfated dextran compounds enhance the efficiency of in vitro BSE PrPSc amplification was unexpected because sulfated dextran has long been known as an antiscrapie agent both in vivo  and in vitro . In vitro studies using recombinant PrP  and PrPC purified from brain homogenate  have suggested that various polyanionic compounds increase the amplification of protease-resistant PrP. Therefore, endogenous polyanionic molecules such as sulfated glycans ,  and RNA  could be cofactors required to facilitate the propagation of PrPSc. Small and negatively charged dextran compounds (DSP and DSS-L) were most effective for in vitro amplification of bovine PrPSc in this study. These dextran compounds may accelerate the rate of PrPSc formation by acting as accessory molecules that facilitate or stabilize interactions between PrPSc, PrPC and cofactors contained in brain homogenates. Since species-specific differences in cofactor preference for in vitro amplification of PrPSc have been reported , dextran compounds may interfere with PrPSc formation by acting as competitive inhibitors of the cofactors required for propagation of scrapie PrPSc.
The theory that PrPSc is widely distributed in various peripheral tissues in the terminal disease stage is strongly supported by our experimental results as well as previous findings, which demonstrated a low level of infectivity in the tonsils  and muscles  of cattle that were orally administered a brain homogenate prepared from BSE-infected cattle. With regard to the level of PrPSc detected in muscle tissue, the level estimated from the amplification factor in PMCA was lower than that found in a brain homogenate diluted to 10−6 because no PrPSc signal was detected in the first round of amplification. In the mesenteric and Rouviere lymph nodes as well as the ileocecal region, only one or two of the quadruplicate samples tested positive, even after four rounds of amplification. Given that PrPSc tends to aggregate, partial detection of PrPSc in the reaction may be due to the near absence of PrPSc; PrPSc levels in these tissues would have been equivalent to the levels found in brain homogenate dilutions of 10−10 to 10−11.
Although significant prionemia  and PrPSc distribution in the blood  have been demonstrated in scrapie-infected animals, the presence of PrPSc in the blood was not substantiated in the BSE-affected cattle used in our study, despite a dramatic improvement in the sensitivity of PrPSc detection. This observation was in agreement with the previous result showing that the disease is not transmitted through the blood of BSE-affected cattle , . Together with the scattered accumulation of PrPSc in the spleen and the low-level accumulation of PrPSc in the lymph nodes, the absence of detectable PrPSc in the blood of BSE-affected cattle suggests a neuronal rather than lymphoreticular progression of BSE PrPSc to the brain.
With regard to other bodily fluids, a bioassay of saliva from CWD-affected deer showed significant levels of infectious prions . The presence of PrPSc in the salivary glands  and the amplification of PrPSc in concentrated buccal swab samples  have been reported in scrapie-infected sheep. Ours is the first report describing PrPSc detection in both the salivary glands and saliva of BSE-infected cattle. The salivary glands are regulated by parasympathetic nerves arising from the salivary nuclei of the medulla oblongata and sympathetic nerves arising from the thoracic portion of the spinal cord. Thus, it is possible that PrPSc accumulated in the central nervous system and spread to the salivary glands through the autonomic nervous system, and that very small amounts of PrPSc were secreted into the saliva in BSE-infected cattle.
Our study demonstrated that the distribution of PrPSc was not restricted to the nervous system, and that PrPSc was able to spread to most of the peripheral tissues examined in the terminal disease stage. The finding that PrPSc could be amplified in saliva taken from an asymptomatic animal suggests a potential usefulness of this technique for BSE diagnosis. Detailed examinations of the temporal course of BSE infection and the incidence of PrPSc appearance in saliva, as well as studies of how infection route affects salivary PrPSc accumulation, will be necessary to confirm whether salivary PrPSc can serve as a reliable marker for BSE infection. The highly sensitive method we describe has other practical applications as well, such as evaluating the safety of livestock products and raw feed materials, and safety assurance of pharmaceutical and cosmetic products manufactured from bovine source materials.
Materials and Methods
All animal experiments were approved by the Animal Care and Use Committee (approval IDs: 450 and 08-009) and Animal Ethics Committee (approval IDs: 04-III-7 and 08-IV-32) of the National Institute of Animal Health.
The cattle used in this study were imported from Australia. A c-BSE-infected brain homogenate (50 ml of a 10% homogenate) was orally administered to cattle (cows 5499, 5468, and 5550) ranging from 10 to 12 months in age. After 34 to 57 months, the animals were sacrificed and dissected in the terminal disease stage. Cow 9007 was intracerebrally inoculated with c-BSE-infected brain homogenate (1 ml of a 10% homogenate), sacrificed and dissected 17 months following inoculation, and the tissues were used for the analysis of salivary PrPSc. Normal 3- to 4- month-old cattle (cows 2914 and 5660) were used as controls.
Tissues, white blood cells (WBCs), plasma, serum, CSF, and saliva were collected upon dissection and stored in small aliquots at −80°C. Oral cavity saliva was collected by aspiration. Samples from each tissue (0.2 g) and WBCs (approximately 2×108 cells) were homogenized and suspended at 20% (w/v) in phosphate-buffered saline (PBS) containing 2× complete protease inhibitors (Roche Diagnostics).
To avoid contamination, brain homogenates were prepared in a laboratory that had never contained infected materials. The brains of bovine PrPC-overexpressing TgBoPrP transgenic mice and PrP knockout (PrP0/0) mice were homogenized separately in 20%(w/v) PBS containing 2× complete protease inhibitors. The homogenates were mixed with an equal volume of elution buffer (PBS containing 2% Triton X-100 and 8 mM EDTA) and incubated at 4°C for 1 h with continuous agitation. After centrifugation at 4500×g for 5 min, the supernatants were mixed in a 5∶1 proportion of PrP0/0:TgBoPrP. This mixture was used as the PrPC substrate. Dextrans (Nacalai), dextran compounds (sodium dextran sulfate (DSS), potassium dextran sulfate (DSP), Nacalai; DEAE-dextran, Sigma), pentosan polysulfate (PPS, Elmiron, Janssen-Ortho), sulfated polysaccharide (λ-carrageenan (λ-Cag), Nacalai), glycosaminoglycans (sodium chondroitin sulfate C (CSS), sodium heparan sulfate (HSS), Nacalai), and heparan sulfate proteoglycan (HSPG, Sigma) were dissolved in PBS or distilled water and added to the PrPC substrate at the concentration indicated in the figures. For the amplification of sheep scrapie PrPSc, normal ICR mouse brains were homogenized in 10% (w/v) PBS containing complete protease inhibitors, 1% Triton X-100, and 4 mM EDTA. After centrifugation at 4500×g for 5 min, the supernatant was used as the PrPC substrate.
To examine the bovine PrPSc detection sensitivity, 100 µl of PrPC substrate containing 0.5% DSP was mixed with 1/100 volume of 10% brain homogenate from cattle infected with c-BSE (infectivity titer = 106.7 LD50/g) , and serial 10-fold dilutions were prepared of the PrPC substrate containing 0.5% DSP. Homogenates of each tissue and WBCs, plasma, serum, CSF, and saliva were diluted 1∶20 with the PrPC substrate containing 0.5% DSP (total volume 100 µl) in an electron beam-irradiated polystyrene tube. Amplification was performed with a fully automatic cross-ultrasonic protein-activating apparatus (Elestein 070-CPR, Elekon Science Corporation) using 40 cycles of sonication in which a 3-s pulse oscillation was repeated five times at 1-s intervals, followed by incubation at 37°C for 1 h with agitation. For the amplification of PrPSc in various tissues from BSE-inoculated and control cattle (Figure 6), the PrPC substrate containing 0.5% DSP was mixed with 1/20 volume of homogenized samples or bodily fluids (total volume 80 µl) in an electron beam-irradiated 8-strip polystyrene tube specially designed for PrPSc propagation. PMCA was performed using 40 cycles of sonication (a pulse oscillation for 5 s, repeated five times at 1-s intervals), followed by incubation at 37°C for 1 h with agitation. The 1∶5 dilution of the PMCA product and subsequent amplification was repeated three times.
Samples (10 µl) were mixed with 10 µl of proteinase K (PK) solution (100 µg/ml) after each round of amplification and incubated at 37°C for 1 h. The digested materials were mixed with 20 µl of 2× SDS sample buffer and incubated at 100°C for 5 min. The samples were separated by SDS-PAGE and transferred onto a polyvinylidene fluoride membrane (Millipore). After blocking, the membrane was incubated for 1 h with a horseradish peroxidase (HRP)-conjugated T2 monoclonal antibody  diluted 1∶10 000. After washing, the blotted membrane was developed using the Immobilon Western Chemiluminescent HRP Substrate (Millipore) according to the manufacturer's instructions. Chemiluminescence signals were analyzed with a Light Capture system (Atto).
A 10% brain homogenate from c-BSE-infected cows was diluted to 10−8 with PrPC substrate containing 0.5% DSP and amplified. The PMCA product was diluted 1∶5 with the PrPC source containing 0.5% DSP, and a second round of amplification was performed. The 1∶5 dilution of the PMCA product and its subsequent amplification were repeated five times. The product from the sixth round was diluted 1∶10 with PBS and inoculated intracerebrally into TgBoPrP mice (20 µl per mouse). The PrPC substrate containing 0.05% DSP and the PrPC substrate containing the PrPSc seed diluted to 3.2×10−12 were inoculated as dilution controls for DSP and the PrPSc seed, respectively.
The left hemisphere of the brain was fixed in 10% buffered formalin for neuropathological analysis. Coronal brain sections were immersed in 98% formic acid to reduce infectivity and embedded in paraffin wax. Sections of 4-µm thickness were cut and stained with hematoxylin and eosin (HE). Immunoreactive PrPSc was detected in brain sections using anti-PrP monoclonal antibody F99/97.6.1 (VMRD) or 12F10 (SPI-bio) as the primary antibody. An anti-mouse universal immunoperoxidase polymer (Histofine simple stain MAX-PO (M), Nichirei) was used as the secondary antibody, and 3,3′-diaminobenzidine tetrachloride served as the chromogen.
We wish to thank the staff of the Prion Disease Research Center of the National Institute of Animal Health for their assistance.
Conceived and designed the experiments: YM. Performed the experiments: YM MY KM HO YI MI YM SF TY. Wrote the paper: YM. Administered the intracerebral inoculation of BSE: SO. Administered the oral inoculation of BSE: TY. Supervised the study: SM.
- 1. Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216: 136–144.SB Prusiner1982Novel proteinaceous infectious particles cause scrapie.Science216136144
- 2. Prusiner SB (1998) Prions. Proc Natl Acad Sci U S A 95: 13363–13383.SB Prusiner1998Prions.Proc Natl Acad Sci U S A951336313383
- 3. Wells GA, Scott AC, Johnson CT, Gunning RF, Hancock RD, et al. (1987) A novel progressive spongiform encephalopathy in cattle. Vet Rec 121: 419–420.GA WellsAC ScottCT JohnsonRF GunningRD Hancock1987A novel progressive spongiform encephalopathy in cattle.Vet Rec121419420
- 4. Wilesmith JW, Wells GA, Cranwell MP, Ryan JB (1988) Bovine spongiform encephalopathy: epidemiological studies. Vet Rec 123: 638–644.JW WilesmithGA WellsMP CranwellJB Ryan1988Bovine spongiform encephalopathy: epidemiological studies.Vet Rec123638644
- 5. Wilesmith JW, Ryan JBM, Atkinson MJ (1991) Bovine spongiform encephalopathy: epidemiological studies on the origin. Vet Rec 128: 199–203.JW WilesmithJBM RyanMJ Atkinson1991Bovine spongiform encephalopathy: epidemiological studies on the origin.Vet Rec128199203
- 6. Collinge J, Sidle KC, Meads J, Ironside J, Hill AF (1996) Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD. Nature 383: 685–690.J. CollingeKC SidleJ. MeadsJ. IronsideAF Hill1996Molecular analysis of prion strain variation and the aetiology of ‘new variant’ CJD.Nature383685690
- 7. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, et al. (1997) Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent. Nature 389: 498–501.ME BruceRG WillJW IronsideI. McConnellD. Drummond1997Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent.Nature389498501
- 8. Hill AF, Desbruslais M, Joiner S, Sidle KC, Gowland I, et al. (1997) The same prion strain causes vCJD and BSE. Nature 389: 448–450.AF HillM. DesbruslaisS. JoinerKC SidleI. Gowland1997The same prion strain causes vCJD and BSE.Nature389448450
- 9. Saborio GP, Permanne B, Soto C (2001) Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 411: 810–813.GP SaborioB. PermanneC. Soto2001Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding.Nature411810813
- 10. Castilla J, Saá P, Hetz C, Soto C (2005) In vitro generation of infectious scrapie prions. Cell 121: 195–206.J. CastillaP. SaáC. HetzC. Soto2005In vitro generation of infectious scrapie prions.Cell121195206
- 11. Saá P, Castilla J, Soto C (2006) Ultra-efficient replication of infectious prions by automated protein misfolding cyclic amplification. J Biol Chem 281: 35245–35252.P. SaáJ. CastillaC. Soto2006Ultra-efficient replication of infectious prions by automated protein misfolding cyclic amplification.J Biol Chem2813524535252
- 12. Murayama Y, Yoshioka M, Yokoyama T, Iwamaru Y, Imamura M, et al. (2007) Efficient in vitro amplification of a mouse-adapted scrapie prion protein. Neurosci Lett 413: 270–273.Y. MurayamaM. YoshiokaT. YokoyamaY. IwamaruM. Imamura2007Efficient in vitro amplification of a mouse-adapted scrapie prion protein.Neurosci Lett413270273
- 13. Kurt TD, Perrott MR, Wilusz CJ, Wilusz J, Supattapone S, et al. (2007) Efficient in vitro amplification of chronic wasting disease PrPRES. J Virol 81: 9605–9608.TD KurtMR PerrottCJ WiluszJ. WiluszS. Supattapone2007Efficient in vitro amplification of chronic wasting disease PrPRES.J Virol8196059608
- 14. Thorne L, Terry LA (2008) In vitro amplification of PrPSc derived from the brain and blood of sheep infected with scrapie. J Gen Virol 89: 3177–3184.L. ThorneLA Terry2008In vitro amplification of PrPSc derived from the brain and blood of sheep infected with scrapie.J Gen Virol8931773184
- 15. Jones M, Peden AH, Prowse CV, Gröner A, Manson JC, et al. (2007) In vitro amplification and detection of variant Creutzfeldt-Jakob disease PrPSc. J Pathol 213: 21–26.M. JonesAH PedenCV ProwseA. GrönerJC Manson2007In vitro amplification and detection of variant Creutzfeldt-Jakob disease PrPSc.J Pathol2132126
- 16. Soto C, Anderes L, Suardi S, Cardone F, Castilla J, et al. (2005) Pre-symptomatic detection of prions by cyclic amplification of protein misfolding. FEBS Lett 579: 638–642.C. SotoL. AnderesS. SuardiF. CardoneJ. Castilla2005Pre-symptomatic detection of prions by cyclic amplification of protein misfolding.FEBS Lett579638642
- 17. Gough KC, Baker CA, Taema M, Maddison BC (2009) In vitro amplification of prions from milk in the detection of subclinical infections. Prion 3: 236–239.KC GoughCA BakerM. TaemaBC Maddison2009In vitro amplification of prions from milk in the detection of subclinical infections.Prion3236239
- 18. Fujihara A, Atarashi R, Fuse T, Ubagai K, Nakagaki T, et al. (2009) Hyperefficient PrPSc amplification of mouse-adapted BSE and scrapie strain by protein misfolding cyclic amplification technique. FEBS J 276: 2841–2848.A. FujiharaR. AtarashiT. FuseK. UbagaiT. Nakagaki2009Hyperefficient PrPSc amplification of mouse-adapted BSE and scrapie strain by protein misfolding cyclic amplification technique.FEBS J27628412848
- 19. Murayama Y, Yoshioka M, Horii H, Takata M, Yokoyama T, et al. (2006) Protein misfolding cyclic amplification as a rapid test for assessment of prion inactivation. Biochem Biophys Res Commun 348: 758–762.Y. MurayamaM. YoshiokaH. HoriiM. TakataT. Yokoyama2006Protein misfolding cyclic amplification as a rapid test for assessment of prion inactivation.Biochem Biophys Res Commun348758762
- 20. Todd NV, Morrow J, Doh-ura K, Dealler S, O'Hare S, et al. (2005) Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease. J Infect 50: 394–396.NV ToddJ. MorrowK. Doh-uraS. DeallerS. O'Hare2005Cerebroventricular infusion of pentosan polysulphate in human variant Creutzfeldt-Jakob disease.J Infect50394396
- 21. Terada T, Tsuboi Y, Obi T, Doh-ura K, Murayama S, et al. (2010) Less protease-resistant PrP in a patient with sporadic CJD treated with intraventricular pentosan polysulphate. Acta Neurol Scand 121: 127–130.T. TeradaY. TsuboiT. ObiK. Doh-uraS. Murayama2010Less protease-resistant PrP in a patient with sporadic CJD treated with intraventricular pentosan polysulphate.Acta Neurol Scand121127130
- 22. Yokoyama T, Masujin K, Yamakawa Y, Sata T, Murayama Y, et al. (2007) Experimental transmission of two young and one suspended bovine spongiform encephalopathy (BSE) cases to bovinized transgenic mice. Jpn J Infect Dis 60: 317–320.T. YokoyamaK. MasujinY. YamakawaT. SataY. Murayama2007Experimental transmission of two young and one suspended bovine spongiform encephalopathy (BSE) cases to bovinized transgenic mice.Jpn J Infect Dis60317320
- 23. Scott MR, Safar J, Telling G, Nguyen O, Groth D, et al. (1997) Identification of a prion protein epitope modulating transmission of bovine spongiform encephalopathy prions to transgenic mice. Proc Natl Acad Sci U S A 94: 14279–14284.MR ScottJ. SafarG. TellingO. NguyenD. Groth1997Identification of a prion protein epitope modulating transmission of bovine spongiform encephalopathy prions to transgenic mice.Proc Natl Acad Sci U S A941427914284
- 24. Deleault NR, Harris BT, Rees JR, Supattapone S (2007) Formation of native prions from minimal components in vitro. Proc Natl Acad Sci U S A 104: 9741–9746.NR DeleaultBT HarrisJR ReesS. Supattapone2007Formation of native prions from minimal components in vitro.Proc Natl Acad Sci U S A10497419746
- 25. Wang F, Wang X, Yuan CG, Ma J (2010) Generating a prion with bacterially expressed recombinant prion protein. Science 327: 1132–1135.F. WangX. WangCG YuanJ. Ma2010Generating a prion with bacterially expressed recombinant prion protein.Science32711321135
- 26. Farquhar CF, Dickinson AG (1986) Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. J Gen Virol 67: 463–473.CF FarquharAG Dickinson1986Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection.J Gen Virol67463473
- 27. Caughey B, Raymond GJ (1993) Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J Virol 67: 643–650.B. CaugheyGJ Raymond1993Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells.J Virol67643650
- 28. Wong C, Xiong LW, Horiuchi M, Raymond L, Wehrly K, et al. (2001) Sulfated glycans and elevated temperature stimulate PrPSc-dependent cell-free formation of protease-resistant prion protein. EMBO J 20: 377–386.C. WongLW XiongM. HoriuchiL. RaymondK. Wehrly2001Sulfated glycans and elevated temperature stimulate PrPSc-dependent cell-free formation of protease-resistant prion protein.EMBO J20377386
- 29. Deleault NR, Geoghegan JC, Nishina K, Kascsak R, Williamson RA, et al. (2005) Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions. J Biol Chem 280: 26873–26879.NR DeleaultJC GeogheganK. NishinaR. KascsakRA Williamson2005Protease-resistant prion protein amplification reconstituted with partially purified substrates and synthetic polyanions.J Biol Chem2802687326879
- 30. Deleault NR, Kascsak R, Geoghegan JC, Supattapone S (2010) Species-dependent differences in cofactor utilization for formation of the protease-resistant prion protein in vitro. Biochemistry 49: 3928–3934.NR DeleaultR. KascsakJC GeogheganS. Supattapone2010Species-dependent differences in cofactor utilization for formation of the protease-resistant prion protein in vitro.Biochemistry4939283934
- 31. Wells GA, Spiropoulos J, Hawkins SA, Ryder SJ (2005) Pathogenesis of experimental bovine spongiform encephalopathy: preclinical infectivity in tonsil and observations on the distribution of lingual tonsil in slaughtered cattle. Vet Rec 156: 401–407.GA WellsJ. SpiropoulosSA HawkinsSJ Ryder2005Pathogenesis of experimental bovine spongiform encephalopathy: preclinical infectivity in tonsil and observations on the distribution of lingual tonsil in slaughtered cattle.Vet Rec156401407
- 32. Buschmann A, Groschup MH (2005) Highly bovine spongiform encephalopathy-sensitive transgenic mice confirm the essential restriction of infectivity to the nervous system in clinically diseased cattle. J Infect Dis 192: 934–942.A. BuschmannMH Groschup2005Highly bovine spongiform encephalopathy-sensitive transgenic mice confirm the essential restriction of infectivity to the nervous system in clinically diseased cattle.J Infect Dis192934942
- 33. Houston F, McCutcheon S, Goldmann W, Chong A, Foster J, et al. (2008) Prion diseases are efficiently transmitted by blood transfusion in sheep. Blood 112: 4739–4745.F. HoustonS. McCutcheonW. GoldmannA. ChongJ. Foster2008Prion diseases are efficiently transmitted by blood transfusion in sheep.Blood11247394745
- 34. Castilla J, Saá P, Soto C (2005) Detection of prions in blood. Nat Med 11: 982–985.J. CastillaP. SaáC. Soto2005Detection of prions in blood.Nat Med11982985
- 35. Wells GAH, Dawson M, Hawkins SAC, Austin AR, Green RB, et al. (1996) Preliminary observations on the pathogenesis of experimental bovine spongiform encephalopathy. In: Gibbs CJJ, editor. Sixth International Workshop on bovine spongiform encephalopathy: the BSE dilemma. New York: Springer-Verlag. pp. 28–44.GAH WellsM. DawsonSAC HawkinsAR AustinRB Green1996Preliminary observations on the pathogenesis of experimental bovine spongiform encephalopathy.CJJ GibbsSixth International Workshop on bovine spongiform encephalopathy: the BSE dilemmaNew YorkSpringer-Verlag2844
- 36. Mathiason CK, Powers JG, Dahmes SJ, Osborn DA, Miller KV, et al. (2006) Infectious prions in the saliva and blood of deer with chronic wasting disease. Science 314: 133–136.CK MathiasonJG PowersSJ DahmesDA OsbornKV Miller2006Infectious prions in the saliva and blood of deer with chronic wasting disease.Science314133136
- 37. Vascellari M, Nonno R, Mutinelli F, Bigolaro M, Di Bari MA, et al. (2007) PrPSc in salivary glands of scrapie-affected sheep. J Virol 81: 4872–4876.M. VascellariR. NonnoF. MutinelliM. BigolaroMA Di Bari2007PrPSc in salivary glands of scrapie-affected sheep.J Virol8148724876
- 38. Maddison BC, Rees HC, Baker CA, Taema M, Bellworthy SJ, et al. (2010) Prions are secreted into the oral cavity in sheep with preclinical scrapie. J Infect Dis 201: 1672–1676.BC MaddisonHC ReesCA BakerM. TaemaSJ Bellworthy2010Prions are secreted into the oral cavity in sheep with preclinical scrapie.J Infect Dis20116721676
- 39. Shimizu Y, Kaku-Ushiki Y, Iwamaru Y, Muramoto T, Kitamoto T, et al. (2010) A novel anti-prion protein monoclonal antibody and its single-chain fragment variable derivative with ability to inhibit abnormal prion protein accumulation in cultured cells. Microbiol Immunol 54: 112–121.Y. ShimizuY. Kaku-UshikiY. IwamaruT. MuramotoT. Kitamoto2010A novel anti-prion protein monoclonal antibody and its single-chain fragment variable derivative with ability to inhibit abnormal prion protein accumulation in cultured cells.Microbiol Immunol54112121